Organization (Other)
GLAXO WELLCOME SA
ClinicalTrials.gov lists GLAXO WELLCOME SA as lead sponsor of 72 trials. It has 23 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers GLAXO WELLCOME SA: 72 lead-sponsored trials and 1 legal-entity registration. Part of GSK PLC.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (40)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| HIV Infections | 119 |
| Acquired Immunodeficiency Syndrome | 57 |
| AIDS-Related Complex | 47 |
| Pneumonia, Pneumocystis | 9 |
| Opportunistic Infections | 7 |
Showing 5 of 40 disease areas.
Trials by start year as sponsor or collaborator (4)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2003 | 1 |
| 2000 | 3 |
| 1999 | 8 |
| 1998 | 2 |
Recruitment duration, a model prediction: none of the 72 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (23)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Abacavir | 28 |
| LAMIVUDINE | 18 |
| Amprenavir | 16 |
| Lamivudine-Zidovudine (3TC-ZDV) | 9 |
| Nelfinavir | 8 |
Showing 5 of 23 approved assets.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 4 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 20 | 2023-10-22 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Glaxo Wellcome S.A. | Aranda De Duero, ES | EMA, FDA, Health Canada |
Biomarker capability evidence (889)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACTG1 | Trial collaborator | Named in trial inclusion criteria |
| ACTG1 | Trial collaborator | Named in trial inclusion criteria |
| ACTG1 | Trial collaborator | Named in trial inclusion criteria |
| ACTG1 | Trial collaborator | Named in trial inclusion criteria |
| ACTG1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 889 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.
Counted at group level under GSK plc: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.